Importantly, this raises a potential concern: patients receiving Mcl-1 inhibitor drugs (as part of anti-cancer therapy) might become more susceptible to severe RSV and influenza virus infection or other respiratory viral diseases, due to the virus being able to replicate uncontrolled when Mcl-1 is suppressed. This evidence concerns the gene MCL1 and cancer.